Gene · 7301
Papers2,825
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
641 to 660 of 2,825
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. | Cancers (Basel) | 2022 | 35884458 | PubTator, text mining | PubMed |
| Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry. | Cancers (Basel) | 2022 | 35884425 | PubTator, text mining | PubMed |
| LncRNA RP3-525N10.2-NFKB1-PROS1 triplet-mediated low PROS1 expression is an onco-immunological biomarker in low-grade gliomas: a pan-cancer analysis with experimental verification. | J Transl Med | 2022 | 35879775 | PubTator, text mining | PubMed |
| The Role of Conformational Dynamics and Allostery in the Control of Distinct Efficacies of Agonists to the Glucocorticoid Receptor. | Front Mol Biosci | 2022 | 35874618 | PubTator, text mining | PubMed |
| Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. | Pharmacol Ther | 2022 | 35872332 | PubTator, text mining | PubMed |
| Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling. | Prostate | 2022 | 35860905 | PubTator, text mining | PubMed |
| The AktiWeb study: feasibility of a web-based exercise program delivered by a patient organisation to patients with hip and/or knee osteoarthritis. | Pilot Feasibility Stud | 2022 | 35859065 | PubTator, text mining | PubMed |
| Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. | J Immunother Cancer | 2022 | 35858709 | PubTator, text mining | PubMed |
| Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer. | Front Pharmacol | 2022 | 35847022 | PubTator, text mining | PubMed |
| Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1. | Cell Mol Gastroenterol Hepatol | 2022 | 35843546 | PubTator, text mining | PubMed |
| Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing. | Front Immunol | 2022 | 35833121 | PubTator, text mining | PubMed |
| Bacillus Calmette-Guérin in Immuno-Regulation of Alzheimer's Disease. | Front Aging Neurosci | 2022 | 35832066 | PubTator, text mining | PubMed |
| Base editing in human cells with monomeric DddA-TALE fusion deaminases. | Nat Commun | 2022 | 35821233 | PubTator, text mining | PubMed |
| VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. | Int J Biol Sci | 2022 | 35813484 | PubTator, text mining | PubMed |
| Profiling the 3D interaction between germ cell tumors and microenvironmental cells at the transcriptome and secretome level. | Mol Oncol | 2022 | 35811571 | PubTator, text mining | PubMed |
| Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis in vitro and in vivo. | Ren Fail | 2022 | 35793478 | PubTator, text mining | PubMed |
| Comprehensive analysis of the novel omicron receptor AXL in cancers. | Comput Struct Biotechnol J | 2022 | 35782741 | PubTator, text mining | PubMed |
| Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities. | Front Pharmacol | 2022 | 35774605 | PubTator, text mining | PubMed |
| Natural killer cell homing and trafficking in tissues and tumors: from biology to application. | Signal Transduct Target Ther | 2022 | 35768424 | PubTator, text mining | PubMed |
| First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. | Invest New Drugs | 2022 | 35767205 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7301/papers?page=33